Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 50Neoplasms 22Pancreatic Neoplasms 21Neoplasm Metastasis 12Lung Neoplasms 12Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 7Breast Neoplasms 7Gliosarcoma 6Glioblastoma 6Salivary Gland Neoplasms 5Rectal Neoplasms 5Glioma 5Colorectal Neoplasms 5Colonic Neoplasms 5Astrocytoma 5Unspecified Adult Solid Tumor, Protocol Specific 4Solid Tumors 4Esophageal Neoplasms 4Tongue Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Lymphoma 3Gallbladder Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Hepatocellular 3Bile Duct Neoplasms 3Advanced Cancers 3Advanced Cancer 3

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Erlotinib Hydrochloride × Clear all
NCT00543504 2020-06-30

Bevacizumab in Multiple Phase I Combinations

M.D. Anderson Cancer Center

Phase 1 Completed
343 enrolled

Advanced Cancer

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
117 enrolled

Advanced Cancer

NCT00895128 2015-07-13

Study of Erlotinib in Combination With Dasatinib

M.D. Anderson Cancer Center

Phase 1 Completed
65 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡